Clinical experience with levetiracetam in idiopathic generalized epilepsy according to different syndrome subtypes

Epileptic Disorders

Volumn 7, Issue 3, 2005, Pages 231-235

  Di Bonaventura, Carlo ^a   Fattouch, Jinane ^a   Mari, Francesco ^a   Egeo, Gabriella ^a   Vaudano, Anna Elisabetta ^a   Prencipe, Massimiliano ^a   Manfredi, Mario ^a   Giallonardo, Anna Teresa ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Add on therapy; Idiopathic generalized epilepsy; Juvenile myoclonic epilepsy; Levetiracetam; Monotherapy

Indexed keywords

CLONAZEPAM; ETHOSUXIMIDE; ETIRACETAM; LAMOTRIGINE; PHENOBARBITAL; VALPROIC ACID;

ADD ON THERAPY; ADULT; ARTICLE; BENIGN CHILDHOOD EPILEPSY; CLINICAL ARTICLE; DRUG EFFICACY; DRUG TOLERABILITY; ELECTROENCEPHALOGRAM; FEMALE; FOLLOW UP; GENERALIZED EPILEPSY; HUMAN; MALE; MONOTHERAPY; MYOCLONUS; MYOCLONUS EPILEPSY; OPEN STUDY; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT OUTCOME;

ANTICONVULSANTS; ELECTROENCEPHALOGRAPHY; EPILEPSY, ABSENCE; FEMALE; HUMANS; MALE; MYOCLONIC EPILEPSY, JUVENILE; PIRACETAM; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 25844458408     PISSN: 12949361     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Betts T, Waegemans T, Crawford P. A multicenter, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2,000mg daily and 4,000mg daily, without titration in patients with refractory epilepsy. Seizure 2000; 9: 80-7.
2. Cohen J. Levetiracetam monotherapy for primary generalised epilepsy. Seizure 2003; 12: 150-3.
3. Commission on Classification and terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989; 30: 389-99.
4. Gallagher MJ, Eisenman LN, Brown KM, et al. Levetiracetam reduces spike-wave density and duration during continuous EEG monitoring in patients with idiopathic generalized epilepsy. Epilepsia 2004; 45: 90-1.
5. Greenhill L, Betts T, Yarrow H. Effect of levetiracetam on resistant juvenile myoclonic epilepsy. Seizure 2002; 11: 531.
6. Krauss GL, Abou-Khalil B, Sheth SG, et al. Efficacy of levetiracetam for treatment of drug-resistant generalized epilepsy. Epilepsia 2001; 42(Suppl 7): 181; [abstract].
7. Krauss GL, Betts T, Abou-Khalil B, Bergey G, Yarrow H, Miller A. Levetiracetam treatment of idiopathic generalized epilepsy. Seizure 2003; 12: 617-20.
8. Kasteleijn-Nolst Trenité DGA, Hirsch E. Levetiracetam: preliminary efficacy in generalized seizures. Epileptic Disord 2003; 5 (Suppl 1): S39-S44.
9. Kasteleijn-Nolst Trenité DGA, Marescaux C, Stodieck S, Edelbroek PM, Oosting J. Photosensitive epilepsy: a model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam. Epilepsy Res 1996; 25: 225-30.
10. Kumar SP, Smith PE. Levetiracetam as add-on therapy in generalised epilepsies. Seizure 2004; 13(7): 475-7.
11. Panayiotopoulos CP. Absence epilepsies. In: Engel Jr. J, Pedley TA, eds. Epilepsy: A Comprehensive Textbook. Philadelphia: Lippincott-Raven, 1997: 2327-46.
12. Smith K, Betts T, Pritchett L. Levetiracetam, a promising option for treatment of juvenile myoclonic epilepsy. Epilepsia 2000; 41 (Suppl): 39.
13. Weber S, Beran RGJ. A pilot study of compassionate use of Levetiracetam in patients with generalised epilepsy. Clin Neurosci 2004; 11(7): 728-31.